Oasmia Pharmaceutical AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more
Oasmia Pharmaceutical AB (OASMY) - Total Liabilities
Latest total liabilities as of September 2025: $16.44 Million USD
Based on the latest financial reports, Oasmia Pharmaceutical AB (OASMY) has total liabilities worth $16.44 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oasmia Pharmaceutical AB - Total Liabilities Trend (2004–2024)
This chart illustrates how Oasmia Pharmaceutical AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oasmia Pharmaceutical AB Competitors by Total Liabilities
The table below lists competitors of Oasmia Pharmaceutical AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BROTHER IND (BI5.SG)
STU:BI5
|
Germany | €227.99 Billion |
|
GRENKELEASING
BE:GLJ
|
Germany | €5.99 Billion |
|
AIM5 Ventures Inc
V:AIME-P
|
Canada | CA$14.27K |
|
Matvareexpressen As
OL:MVE
|
Norway | Nkr132.47 Million |
|
BANK OF GREECE - Dusseldorf Stock Exchang
DU:BGC
|
Germany | €172.57 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Oasmia Pharmaceutical AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oasmia Pharmaceutical AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oasmia Pharmaceutical AB (2004–2024)
The table below shows the annual total liabilities of Oasmia Pharmaceutical AB from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $14.55 Million | -36.38% |
| 2023-12-31 | $22.87 Million | -24.89% |
| 2022-12-31 | $30.45 Million | -31.71% |
| 2021-12-31 | $44.59 Million | -74.78% |
| 2020-12-31 | $176.80 Million | -4.92% |
| 2019-12-31 | $185.96 Million | -16.36% |
| 2018-12-31 | $222.33 Million | -0.32% |
| 2017-12-31 | $223.04 Million | +0.83% |
| 2016-12-31 | $221.21 Million | +16.72% |
| 2015-12-31 | $189.53 Million | +36.49% |
| 2014-12-31 | $138.86 Million | -25.54% |
| 2013-12-31 | $186.48 Million | +47.97% |
| 2012-12-31 | $126.03 Million | +65.10% |
| 2011-12-31 | $76.33 Million | +191.93% |
| 2010-12-31 | $26.15 Million | -30.91% |
| 2009-12-31 | $37.85 Million | +5.45% |
| 2008-12-31 | $35.89 Million | +57.01% |
| 2007-12-31 | $22.86 Million | +117.80% |
| 2006-12-31 | $10.50 Million | +118.84% |
| 2005-12-31 | $4.80 Million | +2.90% |
| 2004-12-31 | $4.66 Million | -- |